Mark L. Bagarazzi MD

Dr. Bagarazzi has been Chief Medical Officer at Inovio Pharmaceuticals since 2010 with responsibility for clinical development, biologics manufacturing, regulatory affairs. He previously directed Worldwide Regulatory Affairs, Vaccines/Biologics at Merck where he was responsible for the licensure of RotaTeq and led development for ZOSTAVAX™. He was faculty at Drexel College of Medicine and HIV/AIDS director at St. Christopher’s Hospital for Children. He lectures at Perelman School of Medicine at the University of Pennsylvania and previously at Johns Hopkins University.

He trained at St. Christopher’s Hospital for Children and completed his pediatric infectious diseases fellowship at the Children’s Hospital of Philadelphia. He was board certified in both Pediatrics and Pediatric Infectious Diseases. He has authored dozens of peer-reviewed scientific papers primarily on DNA vaccines. He received his M.D. with honors from UMDNJ: New Jersey Medical School and holds a B.S. in Electrical Engineering magna cum laude from New Jersey Institute of Technology.